What is the market price of Vemurafenib in 2025?

Vemurafenib/zobovo(Vemurafenib) is a classic BRAF inhibitor, mainly targeting melanoma patients with BRAF V600E gene mutations. As a product of the development of precision medicine, its emergence has given some terminal patients hope for long-term survival. Vemurafenib specifically inhibits the activity of mutated BRAF kinase and blocks the downstream MAPK/ERK signaling pathway, thereby inhibiting the growth and division of tumor cells. This targeted therapy concept is different from traditional chemotherapy. It emphasizes precise intervention on molecular mechanisms and is therefore representative in clinical application.

Globally, vemurafenib has been approved for marketing in many countries and is widely used in the United States, Europe, Japan and other places. With the acceleration of the domestic drug review and approval system, vemurafenib has been launched in China and has been included in the medical insurance catalog. This means that the financial burden on patients has been significantly reduced, and more people with indications can actually benefit. In clinical application, it is often used as first-line or combination therapy, providing new treatment options for melanoma patients. In recent years, with the promotion of BRAF/MEK combination regimen, although the clinical status of vemurafenib has been adjusted, it is still the representative choice of this type of drug.

From a price point of view, when the original drug Zobovo is sold in China, the specification is240mg*56 tablets. The price of a single box is about RMB 5,000. After medical insurance reimbursement, the patient's out-of-pocket payment ratio is significantly reduced. In comparison, the Turkish version of the same specifications in overseas markets sells for about more than 3,000 yuan, which is mainly affected by the exchange rate and the international drug procurement system. In Southeast Asia and other regions, some generic drugs have been approved for marketing. For example, vemurafenib produced in Laos has the same specifications and sells for about 2,000 yuan. This type of generic drugs is basically the same as the original drug in terms of ingredients and dosage, but due to low research and development costs, pricing is often more advantageous.

Reference: https://www.drugs.com/mtm/vemurafenib.html